[go: up one dir, main page]

HK1182937A1 - Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations 23-[12-c] - Google Patents

Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations 23-[12-c]

Info

Publication number
HK1182937A1
HK1182937A1 HK13110265.2A HK13110265A HK1182937A1 HK 1182937 A1 HK1182937 A1 HK 1182937A1 HK 13110265 A HK13110265 A HK 13110265A HK 1182937 A1 HK1182937 A1 HK 1182937A1
Authority
HK
Hong Kong
Prior art keywords
dihydroimidazo
quinazoline
substituted
containing combinations
combinations
Prior art date
Application number
HK13110265.2A
Other languages
English (en)
Chinese (zh)
Inventor
Ningshu Liu
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44144895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1182937(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of HK1182937A1 publication Critical patent/HK1182937A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK13110265.2A 2010-04-16 2013-09-03 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations 23-[12-c] HK1182937A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10160109 2010-04-16
PCT/EP2011/055917 WO2011128407A2 (en) 2010-04-16 2011-04-14 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations

Publications (1)

Publication Number Publication Date
HK1182937A1 true HK1182937A1 (en) 2013-12-13

Family

ID=44144895

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13110265.2A HK1182937A1 (en) 2010-04-16 2013-09-03 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations 23-[12-c]

Country Status (25)

Country Link
US (1) US20130184270A1 (es)
EP (1) EP2558126A2 (es)
JP (1) JP5886271B2 (es)
KR (1) KR20130098155A (es)
CN (1) CN102958540B (es)
AU (1) AU2011240003A1 (es)
BR (1) BR112012026480A2 (es)
CA (1) CA2796253A1 (es)
CL (1) CL2012002887A1 (es)
CO (1) CO6620036A2 (es)
CR (1) CR20120524A (es)
CU (1) CU20120150A7 (es)
DO (1) DOP2012000269A (es)
EA (1) EA201201414A8 (es)
EC (1) ECSP12012261A (es)
HK (1) HK1182937A1 (es)
IL (1) IL222356A0 (es)
MA (1) MA34158B1 (es)
MX (1) MX2012012064A (es)
PE (1) PE20130191A1 (es)
PH (1) PH12012502069A1 (es)
SG (1) SG184550A1 (es)
TN (1) TN2012000493A1 (es)
WO (1) WO2011128407A2 (es)
ZA (1) ZA201208616B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
JO3733B1 (ar) * 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
WO2014160034A1 (en) * 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Aldehyde dehydrogenase-1 modulators and methods of use thereof
EA037577B1 (ru) 2013-04-08 2021-04-16 Байер Фарма Акциенгезельшафт ПРИМЕНЕНИЕ 2-АМИНО-N-[7-МЕТОКСИ-8-(3-МОРФОЛИН-4-ИЛПРОПОКСИ)-2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИН-5-ИЛ]ПИРИМИДИН-5-КАРБОКСАМИДА ИЛИ ЕГО ФИЗИОЛОГИЧЕСКИ ПРИЕМЛЕМОЙ СОЛИ ИЛИ ГИДРАТА И ФАРМАЦЕВТИЧЕСКОЙ КОМПОЗИЦИИ, СОДЕРЖАЩЕЙ УКАЗАННОЕ СОЕДИНЕНИЕ, ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ НЕХОДЖКИНСКОЙ ЛИМФОМЫ (НХЛ)
WO2015082376A2 (en) * 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Use of pi3k-inhibitors
BR112017019188A2 (pt) * 2015-03-09 2018-04-24 Bayer Pharma Aktiengesellschaft Combinações contendo 2,3-di-hidroimidazo[1,2-c] quinazolina substituídas
US20180042929A1 (en) * 2015-03-09 2018-02-15 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EP3426657B1 (en) * 2016-03-08 2022-07-13 Bayer Pharma Aktiengesellschaft 2 amino n [7 methoxy 2, 3-dihydroimidazo-[1, 2-c]quinazolin-5-yl]pyrimidine 5 carboxamides
US11185549B2 (en) 2017-06-28 2021-11-30 Bayer Consumer Care Ag Combination of a PI3K-inhibitor with an androgen receptor antagonist
WO2019118313A1 (en) * 2017-12-13 2019-06-20 Merck Sharp & Dohme Corp. Imidazo [1,2-c] quinazolin-5-amine compounds with a2a antagonist properties

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
ATE411996T1 (de) * 2002-09-30 2008-11-15 Bayer Healthcare Ag Kondensierte azolpyrimidinderivate
JP4323793B2 (ja) 2002-12-16 2009-09-02 キヤノン株式会社 ズームレンズ及びそれを有する光学機器
DE102004037875B4 (de) 2004-08-04 2008-05-08 Siemens Ag Sensorvorrichtung, Verfahren und Vorrichtung zum Überwachen einer Sensorvorrichtung
CA2618218C (en) * 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
US8101799B2 (en) * 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
US8808742B2 (en) * 2008-04-14 2014-08-19 Ardea Biosciences, Inc. Compositions and methods for preparing and using same
EP2168583A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma

Also Published As

Publication number Publication date
KR20130098155A (ko) 2013-09-04
PE20130191A1 (es) 2013-02-21
AU2011240003A1 (en) 2012-11-08
CA2796253A1 (en) 2011-10-20
CO6620036A2 (es) 2013-02-15
EA201201414A1 (ru) 2013-04-30
BR112012026480A2 (pt) 2016-08-16
EP2558126A2 (en) 2013-02-20
CR20120524A (es) 2013-01-09
TN2012000493A1 (en) 2014-04-01
SG184550A1 (en) 2012-11-29
US20130184270A1 (en) 2013-07-18
JP2013525293A (ja) 2013-06-20
PH12012502069A1 (en) 2013-02-04
DOP2012000269A (es) 2012-12-15
WO2011128407A2 (en) 2011-10-20
ZA201208616B (en) 2015-08-26
CN102958540B (zh) 2015-09-02
JP5886271B2 (ja) 2016-03-16
CU20120150A7 (es) 2013-02-26
CL2012002887A1 (es) 2013-01-18
WO2011128407A9 (en) 2011-12-22
MA34158B1 (fr) 2013-04-03
ECSP12012261A (es) 2012-11-30
WO2011128407A3 (en) 2012-02-23
EA201201414A8 (ru) 2013-12-30
MX2012012064A (es) 2012-12-17
IL222356A0 (en) 2012-12-31
CN102958540A (zh) 2013-03-06

Similar Documents

Publication Publication Date Title
HK1182937A1 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations 23-[12-c]
HK1195907A1 (zh) 取代的 -二氫咪唑並 喹唑啉鹽
HK1190712A1 (zh) 芳基氨基醇取代的 -二氫咪唑並 喹啉
EP2619203A4 (en) TRICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND APPLICATIONS THEREOF
SG11201401342VA (en) 5,7-substituted-imidazo[1,2-c]pyrimidines
AP2013007147A0 (en) Use of substituted 2,3-dihydroimidazo[1,2-C]quinyzolines
EP2627358C0 (en) PRETARGETING KIT, METHOD AND MEANS USED THEREIN
EP2558431A4 (en) Narrow psd hydraulic cement-scm blends, and methods for making same
IL229993A (en) 8 - Alkoxy [1,2,4] triazolo [5,1 – c] pyrimidine– 2
EP2581371A4 (en) PYRROLYL-SUBSTITUTED DIHYDROINDOL-2-ON DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USES THEREOF
PL2619278T3 (pl) Kompozycja na bazie 3,3,3-trifluoropropenu
EP2630283A4 (en) TIP OF COMPOSITE MATERIAL
EP2671913A4 (en) NATURAL RUBBER, RUBBER COMPOSITION THEREOF AND TIRES
PL2460684T3 (pl) Obrotowy fotel
PL2469107T3 (pl) Tuleja ślizgowa
TWM385438U (en) Improved multi-purpose socket spanner
GB0913884D0 (en) Telmisartan with diuretic formulations
GB201013257D0 (en) Carbene transfer agents
AU2010901109A0 (en) Adjustable, multi-purpose plus
AU5181P (en) Rusty Schlumbergera truncata
AU2010904907A0 (en) Improved Stool
AU2010901295A0 (en) Stool
TWM387825U (en) Vehicle handle structure
AU2010900460A0 (en) Improved Stanchion
AU2009904464A0 (en) The L Shaped Soap Retriever

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190417